Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-blind, Two-period, Crossover, Withdrawal Study to Assess the Efficacy and Safety of AVTX-803 in Subjects With Leukocyte Adhesion Deficiency Type II (LAD II)

NCT05462587 is registered in ClinicalTrials.gov with AUG Therapeutics as lead sponsor.

NCT NCT05462587
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05462587 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-blind, Two-period, Crossover, Withdrawal Study to Assess the Efficacy and Safety of AVTX-803 in Subjects With Leukocyte Adhesion Deficiency Type II (LAD II)
Lead sponsor
AUG Therapeutics
Phase
Phase 3
Overall status
Recruiting
Start date
July 28, 2022
Completion date
November 30, 2026
Enrollment
4 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

leukocyte adhesion deficiency